Biotronik has secured clearance from the FDA for its BIOMONITOR III injectable cardiac monitor, which is designed for documenting unexplained syncope or suspected arrhythmias. The device, which is 60% smaller than the earlier version, works with a patient app that enables real-time annotation of patients' symptoms and reports system diagnostics to facilitate patient-provider engagement.
Biotronik's 3rd-gen injectable cardiac monitor wins FDA clearance
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.